ClinicalTrials.gg
CompletedNCT06803290Updated Jan 31, 2025

Food Effect Study of VHX-896 in Healthy Volunteers

A Phase 1 interventional study of VHX-896 in Healthy, sponsored by Vanda Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-31.

Sponsored by Vanda Pharmaceuticals · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2022, 3 years 10 months ago, and no results have been posted to the registry.
  • Registered 2 years 7 months after the study started (first participant enrolled Jun 2022, registered Jan 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

A single center, two-period, randomized study to evaluate the food effect of VHX-896 tablets in healthy volunteers

02

Conditions studied

  • Healthy

Keywords

  • VHX-896
  • Food Effect
03

In context

Lead sponsor

Vanda Pharmaceuticals is the lead sponsor of 82 studies on the registry; 17 are open to participants now.

Of its 33 completed or terminated interventional studies of FDA-regulated products, 22 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and/or female participants between 18 to 55 years (inclusive).
  • Have a (BMI) of > 18.0 and \< 30.0 kg/m2; (BMI = weight (kg)/ [height (m)]2).
  • Good health as determined by no deviations from normal in medical history, clinical laboratory determination, ECGs, and physical examinations.
  • No clinically significant medical, psychiatric or sleep disorders.

Exclusion criteria

Exclusion Criteria:

  • Participants with history of drug or alcohol abuse in last 12 months.
  • Participants who suffered from significant physical illness in the 4-week period preceding baseline.
  • Pregnant or nursing (lactating) women.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Sequence A: fed then fasted

    Drug: VHX-896

  • Experimental
    Sequence B: fasted then fed

    Drug: VHX-896

Interventions

06

What researchers measure

Primary outcomes

  1. Comparative bioavailability of VHX-tablets under fed versus fasted conditions.

    As measured by plasma concentrations

    Time frame: 96 Hours

Secondary outcomes

  1. Assessment of safety and tolerability of single dose of VHX-896 tablets

    As measured by the incidence of adverse events and clinically significant changes in laboratory values, ECG parameters, and vital signs.

    Time frame: 17 Days

07

Study locations

1 site
  • Vanda Investigational Site
    Springfield, Missouri 65802, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Dec 2022, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2025
First posted
Jan 31, 2025
StartActual
Jun 21, 2022
Primary completionActual
Dec 27, 2022
CompletionActual
Dec 27, 2022
Last update
Jan 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06803290
Responsible party
Sponsor
First posted
Jan 31, 2025
Start date
Jun 21, 2022
Primary completion
Dec 27, 2022
Completion
Dec 27, 2022
Last update
Jan 31, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Milsaperidone

Start the discussion